Stock Analysis on Net
Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Merck & Co. Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Loans payable and current portion of long-term debt 1.29 0.83 2.72 2.48 1.78 1.81 2.78 1.13 2.28 3.78 2.74 7.98 7.02 2.69 5.21 7.49 4.28 4.09 4.54 3.86
Trade accounts payable 3.68 3.29 3.29 3.41 3.91 3.15 3.25 3.48 4.36 3.60 4.30 4.44 5.02 4.17 3.81 4.21 4.43 3.84 3.74 3.66
Accrued and other current liabilities 14.78 13.90 13.16 12.06 12.97 13.28 12.61 13.17 13.11 15.20 14.21 13.11 14.25 13.02 12.34 12.87 14.87 14.12 13.17 12.24
Income taxes payable 2.48 1.86 1.43 1.74 1.82 1.59 1.34 1.47 1.16 1.02 1.07 1.64 1.72 1.10 1.40 1.22 0.87 1.05 0.76 0.98
Dividends payable 1.86 1.76 1.80 1.77 1.73 1.65 1.65 1.66 1.67 1.78 1.83 1.84 1.83 1.74 1.73 1.87 1.88 1.72 1.71 1.78
Current liabilities 24.09% 21.64% 22.39% 21.46% 22.21% 21.48% 21.63% 20.92% 22.59% 25.38% 24.16% 29.02% 29.84% 22.72% 24.47% 27.66% 26.33% 24.82% 23.92% 22.52%
Long-term debt, excluding current portion 31.58 31.83 32.61 26.04 26.33 26.60 26.78 28.67 29.04 24.50 26.50 26.42 27.69 29.31 28.86 25.48 26.94 27.21 27.12 27.59
Deferred income taxes 0.82 0.95 0.95 1.34 1.64 2.26 2.78 2.88 3.26 1.63 1.64 1.33 1.11 1.98 2.31 2.29 1.74 2.35 2.49 2.23
Other noncurrent liabilities 8.24 6.88 6.95 7.65 7.62 8.09 8.36 9.13 8.93 10.13 10.89 13.47 13.63 13.39 13.74 13.60 14.18 13.30 13.44 14.07
Noncurrent liabilities 40.63% 39.66% 40.52% 35.03% 35.60% 36.94% 37.92% 40.69% 41.22% 36.26% 39.03% 41.22% 42.43% 44.68% 44.91% 41.37% 42.86% 42.87% 43.05% 43.88%
Total liabilities 64.72% 61.30% 62.92% 56.49% 57.81% 58.42% 59.55% 61.61% 63.80% 61.64% 63.18% 70.24% 72.26% 67.41% 69.38% 69.03% 69.19% 67.69% 66.97% 66.40%
Common stock, $0.50 par value 1.68 1.68 1.71 1.66 1.64 1.67 1.67 1.68 1.69 1.91 1.97 1.97 1.95 1.99 1.97 2.11 2.12 2.15 2.13 2.17
Other paid-in capital 41.72 41.56 42.33 41.25 40.66 41.32 41.19 41.51 41.85 47.22 48.56 43.60 43.22 43.97 43.45 46.75 46.99 47.47 47.02 47.07
Retained earnings 50.52 53.48 51.88 57.55 55.96 55.97 54.57 52.74 50.80 55.29 53.79 53.81 51.71 56.91 54.87 56.85 55.22 54.97 53.95 53.51
Accumulated other comprehensive loss -4.84 -4.61 -4.69 -4.53 -4.37 -4.43 -4.04 -4.10 -4.19 -4.91 -5.10 -7.29 -7.24 -7.11 -7.06 -7.53 -7.34 -6.47 -6.39 -6.49
Treasury stock, at cost -53.86 -53.47 -54.19 -52.49 -51.75 -53.00 -53.01 -53.50 -54.03 -61.23 -62.50 -62.44 -62.00 -63.27 -62.74 -67.32 -66.29 -65.91 -63.80 -62.82
Total Merck & Co., Inc. stockholders’ equity 35.23% 38.65% 37.04% 43.45% 42.13% 41.52% 40.38% 38.33% 36.13% 38.28% 36.71% 29.66% 27.64% 32.50% 30.50% 30.86% 30.70% 32.21% 32.91% 33.44%
Noncontrolling interests 0.05 0.05 0.05 0.07 0.06 0.06 0.07 0.07 0.07 0.07 0.10 0.10 0.09 0.09 0.11 0.11 0.11 0.10 0.12 0.16
Total equity 35.28% 38.70% 37.08% 43.51% 42.19% 41.58% 40.45% 38.39% 36.20% 38.36% 36.82% 29.76% 27.74% 32.59% 30.62% 30.97% 30.81% 32.31% 33.03% 33.60%
Total liabilities and equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Merck & Co. Inc. current liabilities as a percentage of total liabilities and equity decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Merck & Co. Inc. noncurrent liabilities as a percentage of total liabilities and equity decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Merck & Co. Inc. total liabilities as a percentage of total liabilities and equity decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Total Merck & Co., Inc. stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Merck & Co. Inc. total Merck & Co., Inc. stockholders’ equity as a percentage of total liabilities and equity increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.